High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trial
et al., PLoS Medicine, doi:10.1371/journal.pmed.1003999, COVIT-TRIAL, NCT04344041 (history)
, High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A.., PLoS Medicine, doi:10.1371/journal.pmed.1003999, COVIT-TRIAL, NCT04344041
RCT comparing single dose 400,000IU and single dose 50,000IU vitamin D in France, showing lower mortality with the higher dose, statistically significant only at day 14.The aHR for days 0-5 was 1.30 [0.31-5.35], compared to 0.11 [0.02-0.52] for days 6-14, which in part may reflect the conversion delay for cholecalciferol treatment. The lower efficacy at day 28 vs. day 14 may in part reflect use of only a single dose.
|
risk of death, 30.0% lower, HR 0.70, p = 0.29, treatment 19 of 126 (15.1%), control 21 of 126 (16.7%), Cox proportional hazards, day 28, intention-to-treat.
|
|
risk of death, 38.0% lower, HR 0.62, p = 0.17, treatment 17 of 121 (14.0%), control 21 of 121 (17.4%), Cox proportional hazards, day 28, per-protocol.
|
|
risk of death, 61.0% lower, HR 0.39, p = 0.049, treatment 8 of 127 (6.3%), control 14 of 127 (11.0%), Cox proportional hazards, day 14, intention-to-treat.
|
|
risk of death, 65.0% lower, HR 0.35, p = 0.03, treatment 7 of 122 (5.7%), control 14 of 122 (11.5%), Cox proportional hazards, day 14, per-protocol.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Annweiler et al., 31 May 2022, Randomized Controlled Trial, France, peer-reviewed, 17 authors, dosage 400,000IU single dose, trial NCT04344041 (history) (COVIT-TRIAL).
Abstract: PLOS MEDICINE
RESEARCH ARTICLE
High-dose versus standard-dose vitamin D
supplementation in older adults with COVID19 (COVIT-TRIAL): A multicenter, open-label,
randomized controlled superiority trial
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Annweiler C, Beaudenon M, Gautier J,
Gonsard J, Boucher S, Chapelet G, et al. (2022)
High-dose versus standard-dose vitamin D
supplementation in older adults with COVID-19
(COVIT-TRIAL): A multicenter, open-label,
randomized controlled superiority trial. PLoS Med
19(5): e1003999. https://doi.org/10.1371/journal.
pmed.1003999
Academic Editor: Suzanne C. Cannegieter, Leiden
University Medical Center, NETHERLANDS
Received: July 12, 2021
Cédric Annweiler ID1*, Mélinda Beaudenon ID1, Jennifer Gautier ID1, Justine Gonsard2,
Sophie Boucher ID3, Guillaume Chapelet4, Astrid Darsonval5, Bertrand Fougère6,
Olivier Guérin7, Marjorie Houvet8, Pierre Ménager9, Claire Roubaud-Baudron ID10,
Achille Tchalla11, Jean-Claude Souberbielle12, Jérémie Riou ID2, Elsa Parot-Schinkel2,
Thomas Célarier13, on behalf of the COVIT-TRIAL study group¶
1 Department of Geriatric Medicine and Memory Clinic, Research Centre on Autonomy and Longevity,
University Hospital, Angers, France; UNIV Angers, UPRES EA 4638, University of Angers, Angers, France,
2 Delegation for Clinical Research and Innovation, Angers University Hospital, Angers, France, 3 Department of
ENT Head and Neck Surgery, University Hospital, Angers, France; MitoLab Team Mitochondrial Medecine
Research Centre, MitoVasc Intitute, UNIV Angers, CNRS UMR6015, INSERM U1083, University of Angers,
Angers, France, 4 Department of Geriatric Medicine and Memory Clinic, Research Centre, University Hospital,
Nantes, France; Inserm UMR1235, Nantes Université, Nantes, France, 5 Department of Pharmacy, Angers
University Hospital, Angers, France, 6 Division of Geriatric Medicine, Tours University Hospital, Tours, France;
Education, Ethics, Health (EA 7505), Tours University, Tours, France, 7 Université Côte d’Azur, Centre
Hospitalier Universitaire de Nice, Service de Médecine Gériatrique et Thérapeutique, Nice, France; Université
Côte d’Azur, CNRS UMR 7284/INSERM U108, Institute for Research on Cancer and Aging Nice (IRCAN),
Faculté de Médecine, Nice, France, 8 Department of Geriatric Medicine, General Hospital, Saumur, France,
9 Department of Geriatric Medicine, General Hospital, Le Mans, France, 10 Pôle de Gérontologie Clinique, CHU
Bordeaux, Bordeaux, France; INSERM 1053, Univ. Bordeaux, Bordeaux, France, 11 Unité de Recherche
Clinique et d’Innovation (URCI) de Gérontologie, Pôle HU Gérontologie Clinique, CHU de Limoges, France;
Université de Limoges, IFR GEIST, Laboratoire UR Vie-Santé (Aging and Digital health Lab) Faculté de Medicine
de Limoges, Limoges, France, 12 Service des Explorations Fonctionnelles, Hôpital Necker-Enfants Malades,
AP-HP, Paris, France, 13 Department of Clinical Gerontology, University Hospital of Saint-Etienne, SaintEtienne, France; Chaire Santé des Ainés, University of Jean Monnet, Saint-Etienne, France
¶ Membership of the COVIT-TRIAL study group is provided in S1 Supplemental Appendix.
* Cedric.Annweiler@chu-angers.fr
Accepted: April 26, 2022
Published: May 31, 2022
Copyright: © 2022 Annweiler et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium,..
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.